Page 2 - Expanded Access Program News Today

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has been approved by the US Food and Drug Administration to expand patient enrollment in its...

Tiziana Life Sciences (US) (TLSA) has released an update. Tiziana Life Sciences reports promising results from its Expanded Access Program, with 70...

Initiated discussions with FDA regarding accelerated approval pathway for CNM-Au8® for the treatment of ALS with the objective of submitting an NDA in 2024Released long-term data from the open-label extension

/PRNewswire/ -- Servier, a global leader in oncology focused on delivering meaningful therapeutic progress for the patients it serves, today announced the FDA...

/PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the...

13.02.2024 - Phase 3 clinical study of RZ358 underway in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025 Benefit shown in individual patient cases with RZ358 for tumor-associated hyperinsulinism (taHI) under Expanded Access ...

CELEBRATION, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced that it will present at the upcoming Oppenheimer

Atara Biotherapeutics, Inc. and Pierre Fabre Laboratories announced that data from the pivotal Phase 3 ALLELE study of tab-cel, approved in the European Union in adults and children two years of age...

Cereno Scientific , a company developing innovative treatments for common and rare cardiovascular disease, today announced that the company has been granted approval by the FDA for Expanded Access,...

/PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has closed...